Fibrate

Fibrates
Drug class
Fenofibrate, one of the most popular fibrates
Class identifiers
Use	hypertriglyceridemia and hypercholesterolaemia
Biological target	PPAR
Clinical data
WebMD	MedicineNet
External links
MeSH	D058607
Legal status
In Wikidata

Clofibrate

Gemfibrozil

Etofibrate

Aluminium clofibrate

In pharmacology, the fibrates are a class of amphipathic carboxylic acids. They are used for a range of metabolic disorders, mainly hypercholesterolemia (high cholesterol), and are therefore hypolipidemic agents.

Members

Fibrates prescribed commonly are:

• Bezafibrate (e.g. Bezalip)
• Ciprofibrate (e.g. Modalim)
• Clofibrate (largely obsolete due to side-effect profile, e.g. gallstones)
• Gemfibrozil (e.g. Lopid)
• Fenofibrate (e.g. TriCor)
• Clinofibrate (e.g. Lipoclin)

Indications

Fibrates are used in accessory therapy in many forms of hypercholesterolemia, usually in combination with statins. Clinical trials do support their use as monotherapy agents. Fibrates reduce the number of non-fatal heart attacks, but do not improve all-cause mortality and are therefore indicated only in those not tolerant to statins.

Although less effective in lowering LDL and triglyceride levels, the ability of fibrates to increase HDL and lower triglyceride levels seems to reduce insulin resistance when the dyslipidemia is associated with other features of the metabolic syndrome (hypertension and diabetes mellitus type 2). They are therefore used in many hyperlipidemias. Fibrates are not suitable for patients with low HDL levels. As per US FDA label change of trichor, it is recommended that the HDL-C levels be checked within the first few months after initiation of fibrate therapy. If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline. Fibrate therapy should not be re-initiated Medwatch

Side effects

Most fibrates can cause mild stomach upset and myopathy (muscle pain with CPK elevations). Since fibrates increase the cholesterol content of bile, they increase the risk for gallstones.

In combination with statin drugs, fibrates cause an increased risk of rhabdomyolysis, idiosyncratic destruction of muscle tissue, leading to renal failure. A powerful statin drug, cerivastatin (Lipobay), was withdrawn because of this complication. The less lipophilic statins are less prone to cause this reaction, and are probably safer when combined with fibrates.

Drug toxicity includes acute kidney injury.

Pharmacology

PPAR

Although used clinically since the 1930s, if not earlier, the mechanism of action of fibrates remained unelucidated until, in the 1990s, it was discovered that fibrates activate PPAR (peroxisome proliferator-activated receptors), especially PPARα. The PPARs are a class of intracellular receptors that modulate carbohydrate and fat metabolism and adipose tissue differentiation.

Activating PPARs induces the transcription of a number of genes that facilitate lipid metabolism.

Fibrates are structurally and pharmacologically related to the thiazolidinediones, a novel class of anti-diabetic drugs that also act on PPARs (more specifically PPARγ)

Fibrates are a substrate of (metabolized by) CYP3A4.

Fibrates have been shown to extend lifespan in the roundworm C. elegans.

See also

• Statin
• Hypertriglyceridemia